scholarly journals Urinary-Based Markers for Bladder Cancer Detection

2020 ◽  
Vol 1 (1) ◽  
pp. 49-61
Author(s):  
Tilman Todenhöfer ◽  
Michele Lodde ◽  
Kim van Kessel ◽  
Renate Pichler ◽  
Antonia Vlahou ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Standard Of Care ◽  
Longitudinal Assessment ◽  
High Throughput Analysis ◽  
Urologic Oncology ◽  
Molecular Alterations ◽  
International Consultation ◽  
Short Period ◽  
Prospective Trials ◽  
Urine Markers

Background The use of urine markers for diagnosis and surveillance has been a topic of broad interest and ongoing controversies in the management of patients with bladder cancer. There has been a constant quest for markers that demonstrate clinical utility. Aim In the framework of the International Consultation on Urological Diseases 2019 on Molecular Biomarkers in Urologic Oncology, a comprehensive review of literature on urinary biomarkers for bladder cancer has been performed. Results Currently available urinary markers include protein-based markers, RNA-based markers, and DNA-based markers. The introduction of high-throughput analysis technologies provides the opportunity to assess multiple parameters within a short period of time, which is of interest for RNA-based, DNA-based, and protein-based marker systems. A comprehensive analysis of molecular alterations in urine samples of bladder cancer patients may be of interest not only for diagnosis and surveillance but also for non-invasive longitudinal assessment of molecular, potentially therapy-relevant, alterations. However, most systems lack prospective validation within well-designed trials and have not been broadly implemented in daily clinical practice. Conclusions Because of limited data from prospective trials, the routine use of any urine marker except cytology is not considered as standard of care in international guidelines. There is an urgent need for prospective trials of urine markers to answer specific clinical questions.

The neoadjuvant management of muscle-invasive bladder cancer (MIBC) in Canada: A national survey of urologists.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 303-303 ◽  
Author(s):  
Srikala S. Sridhar ◽  
Kim N. Chi ◽  
Scott A. North ◽  
Peter C. Black ◽  
Lori Wood ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Renal Function ◽  
Medical Oncology ◽  
Performance Status ◽  
Standard Of Care ◽  
Full Time ◽  
Urologic Oncology ◽  
Poor Renal Function ◽  
Medical Oncologists ◽  
Muscle Invasive

303 Background: There is level 1 evidence and a 5% absolute survival benefit supporting the use of cisplatin-based neoadjuvant chemotherapy (NC) for the management of MIBC. Despite this, it is well known that the majority of eligible patients undergoing cystectomy do not receive NC. We previously surveyed medical oncologists and found that the majority will offer NC to MIBC patients depending on stage, renal function, performance status (PS), and comorbidities. However, the number of MIBC patients being referred for consideration of NC by urologists remains low. The aim of this followup survey to urologists was to better understand their approach to MIBC, and referral patterns for NC. Methods: A survey consisting of 24 questions was administered to Canadian urologists belonging to the Canadian Urologic Oncology Group. Respondents completed the survey and mailed/faxed back their responses. The survey was similar to, but not identical to the previous medical oncology survey. Results: Of the 25 respondents, 21/25 (84%) were academic, >90% were in full-time practice, and 72% were practising for >10 yrs. Most (84%) treated over 20 bladder cancer cases annually. Overall, 22/25 (80%) will offer a NC approach if appropriate. In 2009, 9/24 (38%) sent >6 referrals for NC; 2/24 (25%) sent 5-6 referrals, 6/24 (20%) sent 3-4 referrals, and 5/24 (8%) sent 1-2 referrals. NC was offered as standard of care or to downsize tumors. Initial staging included cystoscopy, CT chest/abdo/pelvis and bone scan. Key factors cited for not offering NC were: T2a disease, GFR <40ml/min, age >85 or PS 3 or 4. Average time from NC to cystectomy was 4-6 wks. Conclusions: The majority of academic urologists in Canada will refer MIBC patients for NC except those with T2a disease, poor renal function, age >85 or poor PS. Non-academic urologists are underrepresented in this survey, and may represent the group facing the greatest challenges in offering NC, due to issues such as access to medical oncology, or lack of local expertise in managing MIBC. Targeting non-academic urologists, and encouraging consultation with a medical oncologist for all patients with MIBC, may lead to increased utilization of NC, and better outcomes in this disease.

scholarly journals Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists

2014 ◽  
Vol 8 (9-10) ◽  
pp. 309 ◽  
Author(s):  
Tina Hsu ◽  
Peter C Black ◽  
Kim N Chi ◽  
Christina M Canil ◽  
Bernie J Eigl ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Renal Function ◽  
Performance Status ◽  
Standard Of Care ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Urologic Oncology ◽  
Canadian Association ◽  
Medical Oncologists ◽  
Muscle Invasive

Introduction: Uptake of neoadjuvant chemotherapy (NC) for muscle-invasive bladder cancer (MIBC) has been low despite evidence of a survival benefit. The primary aim of this study was to better understand why the rates are low and determine what factors specifically influence the decision to recommend NC for MIBC.Methods: A 31-question survey was emailed between 2009 and 2011 to medical oncologists belonging to the Canadian Association of Genitourinary Medical Oncologists (CAGMO); and to urologists belonging to the Canadian Urologic Oncology Group (CUOG). We gathered data on practice characteristics, referrals for NC, factors influencing NC use, and chemotherapy regimens offered. Responses were summarized using descriptive statistics.Results: In total, 26/30 (87%) medical oncologists and 25/84 (30%) urologists, who were primarily academic, completed the survey. Most clinicians (medical oncologists 96%, urologists 88%) recommended NC for MIBC, because they considered it to be the standard of care, but most medical oncologists saw ≤6 referrals annually. Performance status, presence of comorbidities and renal function were key considerations in offering NC. NC was not offered if performance status ≥2 (medical oncologists 38%, urologists 44%), age >80 (medical oncologists 46%, urologists 39%), or glomerular filtration rate ≤40 mL/min (medical oncologists 81%, urologists 50%).Conclusions: Most academic clinicians in Canada believe that cisplatin-based combination NC is the standard of care for MIBC and recommend it for patients with adequate performance status and renal function. Using a multidisciplinary approach to treat this disease may be one strategy to increase referral rates for NC and uptake of NC.

scholarly journals Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View

Cancers ◽  
2021 ◽  
Vol 13 (20) ◽  
pp. 5216
Author(s):  
Justus Körfer ◽  
Florian Lordick ◽  
Ulrich T. Hacker
Keyword(s):  
Gastric Cancer ◽  
Targeted Therapy ◽  
Molecular Characterization ◽  
Gastroesophageal Junction ◽  
Standard Of Care ◽  
Metastatic Gastric Cancer ◽  
Point Of View ◽  
Current Status ◽  
Molecular Alterations ◽  
Definition Of

Gastric cancer is a leading cause of cancer death worldwide. Systemic treatment comprising chemotherapy and targeted therapy is the standard of care in advanced/metastatic gastric cancer. Comprehensive molecular characterization of gastric adenocarcinomas by the TCGA Consortium and ACRG has resulted in the definition of distinct molecular subtypes. These efforts have in parallel built a basis for the development of novel molecularly stratified treatment approaches. Based on this molecular characterization, an increasing number of specific genomic alterations can potentially serve as treatment targets. Consequently, the development of promising compounds is ongoing. In this review, key molecular alterations in gastric and gastroesophageal junction cancers will be addressed. Finally, the current status of the translation of targeted therapy towards clinical applications will be reviewed.

scholarly journals A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer

Oncogene ◽  
2018 ◽  
Vol 37 (14) ◽  
pp. 1911-1925 ◽  
Author(s):  
Damiano Fantini ◽  
Alexander P. Glaser ◽  
Kalen J. Rimar ◽  
Yiduo Wang ◽  
Matthew Schipma ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mouse Model ◽  
Human Muscle ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Molecular Alterations ◽  
Muscle Invasive

Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology

2020 ◽  
Vol 38 (16) ◽  
pp. 1760-1762 ◽  
Author(s):  
Ralph de Vere White ◽  
Primo N. Lara ◽  
Peter C. Black ◽  
Christopher P. Evans ◽  
Marc Dall’Era
Keyword(s):  
Bladder Cancer ◽  
Urologic Oncology ◽  
Pragmatic Strategies

ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary Diversion

2013 ◽  
Vol 63 (1) ◽  
pp. 67-80 ◽  
Author(s):  
Richard E. Hautmann ◽  
Hassan Abol-Enein ◽  
Thomas Davidsson ◽  
Sigurdur Gudjonsson ◽  
Stefan H. Hautmann ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Diversion ◽  
International Consultation

No influence of smoking status on the performance of urine markers for the detection of bladder cancer

2018 ◽  
Vol 144 (7) ◽  
pp. 1367-1373 ◽  
Author(s):  
Susanne Deininger ◽  
J. Hennenlotter ◽  
S. Rausch ◽  
K. Docktor ◽  
E. Neumann ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Smoking Status ◽  
Urine Markers
Sign in / Sign up

Export Citation Format

Share Document